KR101780257B1 - 인플루엔자 바이러스의 제조를 위한 영구 세포주 - Google Patents

인플루엔자 바이러스의 제조를 위한 영구 세포주 Download PDF

Info

Publication number
KR101780257B1
KR101780257B1 KR1020137006640A KR20137006640A KR101780257B1 KR 101780257 B1 KR101780257 B1 KR 101780257B1 KR 1020137006640 A KR1020137006640 A KR 1020137006640A KR 20137006640 A KR20137006640 A KR 20137006640A KR 101780257 B1 KR101780257 B1 KR 101780257B1
Authority
KR
South Korea
Prior art keywords
cell
cells
medium
influenza virus
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137006640A
Other languages
English (en)
Korean (ko)
Other versions
KR20130097191A (ko
Inventor
구드룬 쉬드너
우도 라이흘
Original Assignee
세벡 파마세우티컬스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 세벡 파마세우티컬스 게엠베하 filed Critical 세벡 파마세우티컬스 게엠베하
Publication of KR20130097191A publication Critical patent/KR20130097191A/ko
Application granted granted Critical
Publication of KR101780257B1 publication Critical patent/KR101780257B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020137006640A 2010-08-16 2011-08-16 인플루엔자 바이러스의 제조를 위한 영구 세포주 Active KR101780257B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE102010037008.8 2010-08-16
DE102010037008 2010-08-16
DE102011050353 2011-05-13
DE102011050353.6 2011-05-13
PCT/DE2011/075194 WO2012041311A1 (de) 2010-08-16 2011-08-16 Permanente humane amniozyten zelllinie zur herstellung von influenzaviren

Publications (2)

Publication Number Publication Date
KR20130097191A KR20130097191A (ko) 2013-09-02
KR101780257B1 true KR101780257B1 (ko) 2017-09-21

Family

ID=44936126

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137006640A Active KR101780257B1 (ko) 2010-08-16 2011-08-16 인플루엔자 바이러스의 제조를 위한 영구 세포주

Country Status (19)

Country Link
US (1) US20130344569A1 (enExample)
EP (1) EP2606128B1 (enExample)
JP (1) JP5928843B2 (enExample)
KR (1) KR101780257B1 (enExample)
CN (1) CN103168100B (enExample)
AU (1) AU2011307655B2 (enExample)
BR (1) BR112013003766B1 (enExample)
CA (1) CA2808453C (enExample)
DE (1) DE112011102737A5 (enExample)
DK (1) DK2606128T3 (enExample)
ES (1) ES2524894T3 (enExample)
IL (1) IL224728A (enExample)
MX (1) MX337687B (enExample)
PL (1) PL2606128T3 (enExample)
PT (1) PT2606128E (enExample)
RU (1) RU2565546C2 (enExample)
SG (1) SG187863A1 (enExample)
TW (1) TW201211257A (enExample)
WO (1) WO2012041311A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024537896A (ja) 2021-10-18 2024-10-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アデノウイルス随伴ウイルスポリヌクレオチドを含む真核細胞
AR127674A1 (es) 2021-10-18 2024-02-21 Regeneron Pharma Células de mamífero que comprenden genes cas9 integrados para producir sitios de integración estables, y células de mamífero que comprenden sitios de integración estables y otros sitios
CN121343924A (zh) * 2024-07-15 2026-01-16 干细胞转化研究中心有限公司 极早期干细胞在流感病毒制备、检测和药物筛选中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036615A2 (de) 1999-11-18 2001-05-25 Stefan Kochanek Permanente amniozyten-zelllinie, ihre herstellung und verwendung zur herstellung von gentransfervektoren
US20050170463A1 (en) 1999-04-15 2005-08-04 Abraham Bout Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
US7410798B2 (en) * 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
US6492169B1 (en) * 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
ES2526170T3 (es) * 2004-12-23 2015-01-07 Medimmune, Llc Línea celular MDCK no tumorigénica para propagar virus
ES2402061T3 (es) * 2005-10-17 2013-04-26 Medimmune, Llc Método de aumento de la replicación del virus influenza
DE102005054628A1 (de) 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Verfahren zur Herstellung von permanenten humanen Zelllinien
AU2007347716B2 (en) * 2006-09-15 2013-06-20 Medimmune, Llc MDCK cell lines supporting viral growth to high titers and bioreactor process using the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050170463A1 (en) 1999-04-15 2005-08-04 Abraham Bout Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins
WO2001036615A2 (de) 1999-11-18 2001-05-25 Stefan Kochanek Permanente amniozyten-zelllinie, ihre herstellung und verwendung zur herstellung von gentransfervektoren

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BMC BIOTECHNOLOGY. 2008, vol. 8, no. 1, pp. 21-22.

Also Published As

Publication number Publication date
WO2012041311A1 (de) 2012-04-05
AU2011307655B2 (en) 2015-12-17
MX2013001772A (es) 2013-06-03
EP2606128B1 (de) 2014-09-10
ES2524894T3 (es) 2014-12-15
CA2808453C (en) 2020-05-05
CN103168100B (zh) 2016-04-13
IL224728A (en) 2016-05-31
CA2808453A1 (en) 2012-04-05
TW201211257A (en) 2012-03-16
PL2606128T3 (pl) 2015-02-27
SG187863A1 (en) 2013-03-28
EP2606128A1 (de) 2013-06-26
RU2565546C2 (ru) 2015-10-20
RU2013110786A (ru) 2014-09-27
KR20130097191A (ko) 2013-09-02
BR112013003766B1 (pt) 2021-08-24
JP5928843B2 (ja) 2016-06-01
JP2013537543A (ja) 2013-10-03
BR112013003766A2 (pt) 2016-05-31
CN103168100A (zh) 2013-06-19
AU2011307655A1 (en) 2013-03-21
US20130344569A1 (en) 2013-12-26
DE112011102737A5 (de) 2013-06-06
DK2606128T3 (en) 2014-12-01
MX337687B (es) 2016-03-15
PT2606128E (pt) 2014-12-09

Similar Documents

Publication Publication Date Title
US10329536B2 (en) Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an MDCK cell suspension culture
DK2350268T3 (en) PROCEDURE FOR PRODUCING ADENOVIRUS VECTORS
AU2002338666B2 (en) Multiplication of viruses in a cell culture
KR101309568B1 (ko) 현탁 조류 배아 유래 줄기세포주에서의 바이러스 백신제조방법
Sun et al. Design and characterization of a consensus hemagglutinin vaccine immunogen against H3 influenza A viruses of swine
Liu et al. Enhancing enterovirus A71 vaccine production yield by microcarrier profusion bioreactor culture
AU2011307655B2 (en) Permanent human amniocyte cell lines for producing influenza viruses
JP6851827B2 (ja) 細胞培養中でのウイルスの大規模製造
US20190352615A1 (en) Method for purifying virus
Merten et al. Virus production under suspension conditions
KR102568329B1 (ko) 조류인플루엔자 뉴라미니다아제를 포함하는 바이러스-유사입자 및 이를 이용한 범용 백신
US20250313813A1 (en) Rationally designed single-round infectious virus and methods of use thereof
KR20100017593A (ko) 바이러스의 증식을 위한 ２-단계 온도 프로파일
WO2024188803A1 (en) Production of poxviruses from quail cell cultures
WO2024188802A1 (en) Methods of isolating poxviruses from avian cell cultures
Vázquez Ramírez Process intensification for the production of MVA and influenza A virus in high density suspension cultures of AGE1. CR. pIX cells
Schwarzer et al. METABOLISM OF AVIAN DESIGNER CELLS DURING INFLUENZA AND MVA PRODUCTION

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20200710

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20210617

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20220621

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 9